A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
Public ClinicalTrials.gov record NCT04458857. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to evaluate the efficacy of fremanezumab as compared to placebo for the preventive treatment of episodic migraine (EM). Secondary objectives are to further demonstrate the efficacy of fremanezumab as compared to placebo for the preventive treatment of EM, to evaluate the safety and tolerability of fremanezumab in the preventive treatment of EM and to evaluate the immunogenicity of fremanezumab and the impact of antidrug antibodies (ADAs) on clinical outcomes in participants exposed to fremanezumab. The total duration of the study is planned to be up to 51 months.
Study identification
- NCT ID
- NCT04458857
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 235 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 6 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 15, 2020 (Actual)
- Primary completion
- Mar 13, 2024 (Actual)
- Completion
- Mar 13, 2024 (Actual)
- Last update posted
- Jun 22, 2026
2020 – 2024
United States locations
- U.S. sites
- 45
- U.S. states
- 26
- U.S. cities
- 41
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 14281 | Little Rock | Arkansas | 72202 | — |
| Teva Investigational Site 14253 | Banning | California | 92220 | — |
| Teva Investigational Site 14370 | Loma Linda | California | 92354 | — |
| Teva Investigational Site 14322 | Los Angeles | California | 90027 | — |
| Teva Investigational Site 14361 | Sacramento | California | 95815 | — |
| Teva Investigational Site 14319 | Aurora | Colorado | 80045 | — |
| Teva Investigational Site 14368 | Colorado Springs | Colorado | 80907 | — |
| Teva Investigational Site 14244 | Jacksonville | Florida | 32256 | — |
| Teva Investigational Site 14325 | Miami | Florida | 33155 | — |
| Teva Investigational Site 14250 | West Palm Beach | Florida | 33407 | — |
| Teva Investigational Site 14255 | West Palm Beach | Florida | 33409 | — |
| Teva Investigational Site 14243 | Atlanta | Georgia | 30328 | — |
| Teva Investigational Site 14258 | Savannah | Georgia | 31406 | — |
| Teva Investigational Site 14263 | Hoffman Estates | Illinois | 60169 | — |
| Teva Investigational Site 14283 | Park Ridge | Illinois | 60068 | — |
| Teva Investigational Site 14245 | Wichita | Kansas | 67206 | — |
| Teva Investigational Site 14327 | Louisville | Kentucky | 40202 | — |
| Teva Investigational Site 14360 | Covington | Louisiana | 70433 | — |
| Teva Investigational Site 14365 | Baltimore | Maryland | 21201 | — |
| Teva Investigational Site 14317 | Silver Spring | Maryland | 26505 | — |
| Teva Investigational Site 14246 | Waltham | Massachusetts | 02451 | — |
| Teva Investigational Site 14251 | Ann Arbor | Michigan | 48104 | — |
| Teva Investigational Site 14270 | Minneapolis | Minnesota | 55402 | — |
| Teva Investigational Site 14376 | Ridgeland | Mississippi | 39157 | — |
| Teva Investigational Site 14256 | Bridgeton | Missouri | 63044-2513 | — |
| Teva Investigational Site 14371 | New Brunswick | New Jersey | 08901 | — |
| Teva Investigational Site 14276 | Amherst | New York | 14226 | — |
| Teva Investigational Site 14377 | Durham | North Carolina | 27710 | — |
| Teva Investigational Site 14248 | Raleigh | North Carolina | 27607 | — |
| Teva Investigational Site 14264 | Cincinnati | Ohio | 45229-3039 | — |
| Teva Investigational Site 14257 | Oklahoma City | Oklahoma | 73112 | — |
| Teva Investigational Site 14275 | Oklahoma City | Oklahoma | 73116 | — |
| Teva Investigational Site 14363 | Tulsa | Oklahoma | 74136 | — |
| Teva Investigational Site 14364 | Philadelphia | Pennsylvania | 19104-4318 | — |
| Teva Investigational Site 14374 | Bristol | Tennessee | 37620 | — |
| Teva Investigational Site 14252 | Austin | Texas | 78731 | — |
| Teva Investigational Site 14273 | Austin | Texas | 78759 | — |
| Teva Investigational Site 14274 | Bellaire | Texas | 77401 | — |
| Teva Investigational Site 14367 | Dallas | Texas | 75235-7701 | — |
| Teva Investigational Site 14312 | Houston | Texas | 77087 | — |
| Teva Investigational Site 14366 | San Antonio | Texas | 78207 | — |
| Teva Investigational Site 14241 | San Antonio | Texas | 78240 | — |
| Teva Investigational Site 14375 | Salt Lake City | Utah | 84109 | — |
| Teva Investigational Site 14323 | Norfolk | Virginia | 23510 | — |
| Teva Investigational Site 14277 | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 44 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04458857, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 22, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04458857 live on ClinicalTrials.gov.